Dabrafenib has demonstrated antitumor activity in several BRAF-mutated malignancies including melanoma, colorectal carcinoma, papillary thyroid carcinoma, NSCLC, and ovarian carcinoma[10]. This evidence concerns the gene BRAF and ovarian carcinoma.